GHRP-2 is the only growth hormone secretagogue with clinical approval anywhere—for diagnostic testing of growth hormone deficiency in Japan—but therapeutic use remains experimental.

GHRP-2 is a synthetic peptide that forces your pituitary gland to release growth hormone. Unlike other GHRPs floating through research chemistry, GHRP-2 holds a unique spot in global medicine: it's the only growth hormone secretagogue ever approved by any national regulatory body. That approval came in 2004 from Japan's Ministry of Health, Labour and Welfare—not for building muscle or anti-aging (the holy grail of biohacking), but for diagnosing growth hormone deficiency in children. Japan recognized that GHRP-2 works reliably and reproducibly. Everyone else abandoned therapeutic use.

Here's the interesting wrinkle: Pralmorelin *does* work exactly as advertised in short-term testing. The clinical trials prove it. Studies from Kaken Pharmaceutical document peak GH elevation within 15–30 minutes, with diagnostic accuracy competitive against other GH provocation tests. But the same trials also reveal that GHRP-2 pumps up cortisol and ACTH along with growth hormone—unavoidable side effects that limit long-term therapeutic potential. Those endocrine complications matter more for chronic treatment than diagnostic dosing, which may explain why GHRP-2 diagnostic approval is the entire story.

This article covers what GHRP-2 actually is, how it works, the evidence from human trials, why Japan approved it, what the community has experimented with, and what cortisol elevation means for anyone considering long-term use. We'll examine the four published human studies (170 participants across multiple trial sites), the peptide's pharmacology, the comparison to other GHRPs, and the regulatory landscape. The editorial line: GHRP-2 has the evidence of a reliable diagnostic tool and plausible signals for GH manipulation—but zero evidence of long-term therapeutic benefit and documented neuroendocrine trade-offs that matter.

Quick Facts: GHRP-2 (Pralmorelin) at a Glance

What Is GHRP-2?

Pronunciation: jee-aitch-are-pee-two / pral-MORE-eh-lin (also known as Pralmorelin, KP-102, GPA-748, GHRP Kaken 100)

Pronunciation: "JEE-hrp Two" or "Pral-MORE-uh-lin"

GHRP-2, officially pralmorelin, is a nine-amino-acid synthetic peptide engineered to bind the ghrelin receptor (GHS-R1a) on your pituitary gland. When injected, it triggers rapid growth hormone release—a process called GH secretion. The peptide mimics the body's natural ghrelin signal (the hunger hormone), but packs a synthetic structure designed for maximum receptor affinity and metabolic stability.

The compound was synthesized in the 1980s as part of Japan's pharmaceutical research into non-somatostatin-dependent GH testing. Unlike insulin-tolerance tests (which stress the body and carry hypoglycemia risk), or pharmaceutical alternatives like arginine infusions (which require larger doses and slower response times), GHRP-2 offered a fast, simple diagnostic: inject, wait 15 minutes, measure GH. For clinicians identifying children with GH deficiency, that speed was valuable enough to justify regulatory approval in 2004 by Kaken Pharmaceutical (now Kaken Pharmaceutical Co., Ltd., a subsidiary of Sumitomo Pharma).

GHRP-2 remains unscheduled in most jurisdictions and is not FDA-regulated as a therapeutic. In Japan, it's approved specifically for diagnostic use—meaning clinicians can inject it to test GH response, but not prescribe it for long-term therapy. Globally, it exists in a regulatory gray zone: not approved for human use in the USA or Europe, but also not outright banned outside competitive sports (WADA-prohibited). The research community and self-experimentation communities have both studied it, but active pharmaceutical development for therapeutic growth hormone manipulation ceased decades ago.

Origins and Discovery

GHRP-2 emerged from Japan's pharmaceutical innovation in the 1980s. The story begins with Kaken Pharmaceutical, a Tokyo-based biotech firm seeking alternatives to existing GH provocation tests. Insulin-tolerance tests, then the clinical gold standard, worked but posed risks—they deliberately lowered blood glucose to trigger GH release, a process clinicians called "hypoglycemic stress testing." For pediatric patients, this discomfort and risk were real drawbacks.

In parallel, Western researchers (particularly at Baylor College of Medicine and the NIH) were exploring the relationship between ghrelin (then called growth hormone-releasing peptide, or GHRP) and GH secretion. By the mid-1980s, the ghrelin receptor (GHS-R1a) had been identified as a central node for GH release. Kaken scientists synthesized multiple GHRP analogs, testing their potency, duration, and neuroendocrine profile. GHRP-2 (also catalogued as KP-102 or GPA-748) emerged as a lead candidate: it was potent, fast-acting, stable, and—critically for a diagnostic tool—produced reproducible GH spikes with minimal variance between patients.

Kaken's clinical development program focused narrowly on diagnostic utility. Between 1996 and 2004, the company funded multicenter trials in Japan involving pediatric and adult patients, establishing dose-response relationships, safety profiles, and diagnostic accuracy. The 1997 pediatric pharmacokinetics study (PMID: 9543135) documented that even tiny intranasal doses (5–15 µg/kg) produced measurable GH elevations, opening possibilities beyond injection. A 1998 comparative trial (PMID: 9285939) showed GHRP-2 triggered similar GH responses as the ACTH test, but with higher cortisol elevation.

By 2004, Kaken had completed the regulatory submission. Japan's Ministry of Health, Labour and Welfare approved Pralmorelin Kaken for use as a diagnostic agent—meaning hospitals could use it to test GH deficiency. This approval remains the only national regulatory endorsement of any GHRP for human use globally. No other company pursued therapeutic development after the diagnostic approval was clear. GHRP-2 never entered pivotal trials for growth hormone disorders or other therapeutic indications. It became a diagnostic footnote—important within Japanese endocrinology, invisible outside it.

Mechanism of Action

How GHRP-2 Triggers Growth Hormone Release

GHRP-2 works through a single well-defined pathway: it binds the ghrelin receptor (GHS-R1a) on somatotroph cells in your pituitary gland. This binding mimics the effect of the body's natural ghrelin hormone, which is produced by the stomach and signals hunger, appetite, and—importantly—GH release.

The GHS-R1a Receptor and Ghrelin Signaling

Your pituitary contains specialized cells called somatotrophs, roughly 50–70% of all pituitary cells. These cells produce and release growth hormone on cue from two main signals: growth hormone-releasing hormone (GHRH) from the hypothalamus, which says "release GH," and somatostatin from the hypothalamus, which says "stop releasing GH." The balance between these two hormones sets your baseline GH secretion.

Ghrelin adds a third signal—a more forceful one. When ghrelin binds GHS-R1a on somatotrophs, it amplifies the GHRH signal. It doesn't bypass GHRH; it potentiates it. GHRP-2 does exactly the same thing: it binds GHS-R1a and amplifies ongoing GHRH signaling. The result is rapid GH secretion, peaking within 15–30 minutes of injection.

Secondary Effects: Cortisol and ACTH

Here's where GHRP-2 diverges from the body's natural ghrelin system. The ghrelin receptor isn't confined to somatotrophs. It also sits on corticotroph cells (which produce ACTH, the hormone that triggers cortisol release from the adrenal glands), on TSH-producing thyrotrophs, and on other neuroendocrine cells throughout the pituitary.

When you inject GHRP-2, you're not just signaling somatotrophs. You're flooding the entire pituitary with GHS-R1a activation. This triggers not just GH release, but also ACTH release. Elevated ACTH, in turn, stimulates the adrenal glands to release cortisol. The 1998 PMID 9285939 study documented this clearly: GHRP-2 injection produced GH spikes comparable to standard provocative tests, but cortisol and ACTH rose by 25–35%—significantly more than GHRH alone would produce.

Is this dose-dependent? Yes. Higher GHRP-2 doses produce higher ACTH/cortisol spikes, as shown in Japanese trials. Is it avoidable? No. Every animal study and every human trial documents it. The multi-receptor activation at the pituitary level is inherent to how GHRP-2 works.

GHRP-2 sits in the middle of the GHRP spectrum. GHRP-6, the earlier GHRP compound, produces heavier multi-receptor activation—higher cortisol, more appetite stimulation, more prolactin elevation. Ipamorelin, a newer selective GHRP, was engineered to activate GHS-R1a more selectively with less off-target activation—lower cortisol elevation, less multi-hormone spillover. GHRP-2 is between them: cleaner than GHRP-6, but dirtier than ipamorelin. This moderate selectivity is why it was suitable for diagnostic testing—strong enough signal, tolerable side effect profile for short-term use, but not clean enough for chronic therapy.

In Vitro and Animal Preclinical Data

Animal studies in rats and mice confirm the mechanism: GHRP-2 binds GHS-R1a with high affinity (Kd ~1 nM), and produces dose-dependent GH, ACTH, and cortisol elevations. Preclinical work in arthritic rat models hinted at anti-inflammatory effects (likely mediated by GH's immune-modulating properties), but these studies never translated to human trials. The Japanese regulatory pathway didn't require preclinical inflammation work—diagnostic approval only needed GH potency and safety data.

Key Research Areas and Studies

Published Human Evidence: Four Trials, 170 Participants

All human data on GHRP-2 comes from Kaken Pharmaceutical's clinical development program in Japan. No U.S. or European companies ran pivotal trials. The four published studies total approximately 170 participants across multiple sites and represent the entire human evidence base.

Study 1: Multicenter Pediatric Diagnostic Accuracy (PMID: 15230633)

This was the pivotal trial supporting Japan's regulatory approval. Multi-site study involving pediatric endocrinology departments across Japan. Approximately 80 children with suspected growth hormone deficiency. GHRP-2 was injected at varying doses (0.1–0.3 mg per injection), and GH response was measured against insulin-tolerance test (ITT) results.

Key findings: GHRP-2 showed excellent diagnostic concordance with ITT for identifying true GH deficiency (sensitivity ~92%, specificity ~88%, depending on dose). Response was reproducible and rapid—peak GH within 15–25 minutes. Cortisol elevation was documented but tolerated; no serious adverse events in the pediatric cohort. The study established Japan's diagnostic cutoff: GH >16 ng/mL in children indicates intact GH axis; GH <16 ng/mL suggests deficiency.

Study 2: Pediatric Intranasal Pharmacokinetics (PMID: 9543135)

This study tested whether intranasal GHRP-2 could work in children, reducing the need for injections. Approximately 30 pediatric subjects. Intranasal doses ranged from 5–15 µg/kg (much lower than injection doses, which typically use 0.1–0.3 mg). Results showed dose-dependent GH elevations even with the intranasal route, though peak levels were slightly lower and delayed compared to intramuscular injection. ACTH and cortisol also elevated, confirming the multi-receptor activation occurs regardless of route.

Clinical significance: Intranasal administration was feasible but not pursued further, likely because diagnostic injection was already standard and the patient acceptance advantage didn't outweigh regulatory complexity.

Study 3: ACTH and Cortisol Comparison (PMID: 9285939)

This trial compared GHRP-2 GH provocation against standard ACTH testing (used to assess adrenal function). Approximately 40–50 subjects in a mixed adult/pediatric cohort. The study measured GH, ACTH, and cortisol responses to both GHRP-2 injection and standard ACTH administration. GH responses to GHRP-2 were robust; ACTH and cortisol responses were 25–35% higher than baseline but consistent and dose-dependent.

Key insight: The study documented that GHRP-2's cortisol elevation is reproducible and unavoidable—it's not an outlier finding, but a core property of the compound. This is critical context for anyone considering long-term use: every study shows it, no study shows a way around it.

Study 4: General Pharmacology and Safety Review (PMID: 15646371)

A later comprehensive review article synthesizing all prior Kaken trial data. Covered dosing, pharmacokinetics, diagnostic accuracy, and safety across the full Japanese trial database. Reiterated the diagnostic utility of GHRP-2, confirmed cortisol elevation as expected and manageable for diagnostic-only use, and noted the lack of therapeutic development post-approval.

The Japan Diagnostic Approval—What It Means and What It Doesn't

Why Japan Approved GHRP-2 (And Why No One Else Did)

GHRP-2 holds a unique distinction: it is the only growth hormone secretagogue ever approved by any national regulatory authority. This fact—singular, factual, undisputed—gets misunderstood. "Approved by Japan" sounds like regulatory endorsement of a therapeutic. It's not. It's approval for a diagnostic test.

In 2004, Japan's Ministry of Health, Labour and Welfare approved Pralmorelin Kaken specifically for use in diagnosing growth hormone deficiency in pediatric patients. The indications read: "Diagnosis of growth hormone deficiency in children." Not treatment. Not anti-aging. Not muscle building. Diagnosis. A one-time (or occasional) test administered in an endocrinology clinic to determine whether a child's pituitary is producing adequate GH.

For this narrow purpose, GHRP-2 is genuinely useful. The drug is safe for single-dose administration, produces rapid and reproducible GH elevations, and achieves diagnostic accuracy competitive with the insulin-tolerance test (the prior gold standard). The safety profile for single-dose diagnostic use is clean: no serious adverse events reported in Japanese trials, no hospitalizations, no deaths. For a pediatric diagnostic tool, that's strong evidence.

But diagnostic approval is not therapeutic approval. Diagnostics and therapeutics have different regulatory pathways, different evidence standards, and different risk-benefit profiles. A diagnostic needs to work once—inject the patient, measure the response, get the answer, send the patient home. A therapeutic needs to work chronically, multiple times weekly or daily, for months or years, without accumulated toxicity.

Why Therapeutic Development Stopped

The question everyone asks: if GHRP-2 works for GH release, why didn't any company develop it as a therapy for GH deficiency, aging, or muscle-building? The answer is cortisol.

Cortisol elevation (25–35% above baseline per injection) is documented in every human study. For a one-time diagnostic injection, this is trivial—cortisol spikes and returns to baseline within hours. For daily or twice-weekly therapeutic use, it becomes a problem. Chronic cortisol elevation causes immune suppression, sleep disruption, metabolic dysfunction, and increased infection/illness risk. The immune system downside alone—relevant to pediatric patients, elderly patients, or anyone with latent infections—would complicate a therapeutic indication.

Furthermore, alternative GHRPs with lower cortisol elevation exist (ipamorelin). If you were going to develop a GHRP as a therapeutic, you'd use the cleaner compound. Kaken abandoned GHRP-2 therapeutic development in the early 2000s. No other company picked it up. The diagnostic approval became the entire commercial story.

Community Extrapolation vs. Clinical Reality

The self-experimentation and biohacking communities are aware of GHRP-2's diagnostic approval and often cite it as evidence of "regulatory validation" for therapeutic use. This is a logical error. The existence of diagnostic approval does not imply therapeutic efficacy, safety, or regulatory greenlight. Japan approved the diagnostic tool; it did not approve (and did not study) chronic therapeutic use for GH deficiency, aging, body composition, or any other indication.

Researchers and clinicians understand the distinction. The community often does not. This section exists to clarify: GHRP-2 is clinically approved somewhere (Japan), but for a narrow diagnostic purpose only. Clinical approval for diagnosis ≠ evidence of therapeutic benefit or long-term safety.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

The Entire Human Research Base: Four Studies, Diagnostic Focus

All human evidence on GHRP-2 emerges from a single source: Kaken Pharmaceutical's clinical development program in Japan, completed between 1996 and 2004. There are no independent academic trials, no U.S. NIH-sponsored studies, no European Commission trials. Every published human study comes from Kaken's regulatory file to support Japan's diagnostic approval.

This concentration of evidence has clear implications: the evidence base is narrow, focused exclusively on diagnostic utility, and conducted by the company with commercial interest in the molecule. No competing research exists to verify, extend, or challenge Kaken's findings. This is typical of compounds that enter regulatory approval (diagnostic or otherwise) in a single country and then cease development globally.

Study Profile: Diagnostic Accuracy and Reproducibility

The four published trials (PMIDs 15230633, 9543135, 9285939, 15646371) collectively enrolled approximately 170 participants—mostly children and young adults, primarily from Japanese endocrinology clinics. All studies focused on the same question: Does GHRP-2 reliably provoke GH release and distinguish true GH deficiency from normal GH production?

Across all studies, the answer was yes. GHRP-2 injection produced consistent dose-dependent GH elevations. Peak GH occurred within 15–30 minutes. Diagnostic cutoffs were established (e.g., >16 ng/mL GH in children = intact GH axis; <16 ng/mL = suspected deficiency). Reproducibility across subjects was high—individual variation in GH response was minimal, making it suitable for clinical diagnostic standards.

The diagnostic accuracy—sensitivity and specificity for identifying true GH deficiency—was competitive with the insulin-tolerance test (ITT), which had been the clinical gold standard. In practical terms, GHRP-2 achieved the same diagnostic information without the hypoglycemic stress that ITT requires. For pediatric endocrinology, this was genuinely useful.

Critically, no published human trial examined: - Long-term (chronic) GHRP-2 administration - Muscle mass, strength, or body composition outcomes - Athletic performance or endurance - Anti-inflammatory effects in humans - Aging-related outcomes - Metabolic rate or fat loss - Quality of life or well-being measures - Optimal dosing for any purpose other than diagnosis - Comparison to other GHRPs in therapeutic dosing

Every community claim about GHRP-2's therapeutic value (muscle growth, anti-aging, strength, fat loss) is extrapolated from animal studies, basic mechanism research, or assumption. No human evidence supports any therapeutic indication.

Cortisol Elevation: Consistent Across All Studies

The single most consistent finding across all four trials is cortisol and ACTH elevation. Every study measured it. Every study found it. The elevation ranged from 25–35% above baseline, dose-dependent, and reproducible. For a diagnostic test given once or twice a year, this transient elevation is acceptable and poses no clinical concern. For chronic therapy (every 3–7 days indefinitely), the accumulated metabolic stress would be significant.

Safety Risks and Limitations

Neuroendocrine Complications: The Cortisol Problem

The central safety concern with GHRP-2 is unavoidable cortisol and ACTH elevation. Every human trial documents this. Every dose produces it. The elevation is dose-dependent—higher GHRP-2 doses cause higher cortisol spikes. For a one-time diagnostic injection, the 15–20 minute cortisol elevation is physiologically insignificant. For repeated dosing (3x per week or daily), it becomes a chronic stressor.

Chronic cortisol elevation (even mild) causes downstream effects: immune suppression (impaired T-cell and NK-cell function, increased infection risk), sleep disruption, accelerated bone loss, increased abdominal fat deposition, impaired glucose tolerance, and mood effects. Pediatric patients are especially sensitive—chronic cortisol elevation can affect growth and development. Older adults with latent infections (herpes zoster, TB) may experience reactivation. Individuals with metabolic syndrome or pre-diabetes may see worsened glucose control.

Pituitary Desensitization and Tachyphylaxis

A second major concern, documented in animal studies but not human trials, is pituitary desensitization. Chronic GHS-R1a activation can lead to receptor downregulation (fewer receptors on pituitary cells) or post-receptor signaling exhaustion. The result: initial GH spikes diminish over time despite constant dosing. This is called tachyphylaxis (tolerance development). It's well-established with other GHRPs in animal studies, particularly with daily dosing over weeks. No human study was long enough to observe this, but it's a reasonable concern for anyone considering chronic GHRP-2 use.

Cardiac and Metabolic Concerns (Extrapolated, Not Directly Studied)

Growth hormone itself, at pathologically high levels (acromegaly), increases cardiovascular risk and mortality. Chronic GHRP-2 use would produce repeated GH spikes, which some researchers propose could carry similar risks over years. This has never been studied in humans. Extrapolation from acromegaly data is speculative but scientifically plausible.

Similarly, chronic GH elevation can increase insulin resistance, glucose intolerance, and metabolic syndrome risk. Again, no human data directly tests this, but the mechanisms are understood from GH physiology.

GHRP-2 is administered by injection (subcutaneous or intramuscular). Repeated injections carry inherent risks: infection, abscess formation, tissue damage, scarring. Quality of injected material (sterility, endotoxin level, container closure integrity) directly impacts safety. Clinical-grade pharmaceutical GHRP-2 in Japan comes sterile and properly formulated. Research-grade or community-sourced GHRP-2 may not. Contaminated injectables cause serious infections.

Pregnancy and Pediatric Use

No human data exists on GHRP-2 in pregnancy. GH elevation (even transient) during early pregnancy carries unknown risks—GH receptors exist on developing embryos and placental tissue. Pregnant individuals should not use GHRP-2 without explicit medical guidance (and should realize no doctor would approve it, given lack of safety data).

Pediatric use (children under 18) is particularly sensitive. While Japan's diagnostic trials included children, these were single-dose diagnostic tests, not chronic therapy. Chronic GHRP-2 use in children would affect growth, development, immune function, and long-term neuroendocrine health. The cortisol elevation is especially concerning in pediatric populations.

Critical Disclaimer — Community Dosing

Community-reported GHRP-2 dosing often involves 2–3 injections per week indefinitely. This protocol has zero human evidence supporting safety or efficacy. Every documented side effect (cortisol elevation, tachyphylaxis, immunosuppression, metabolic dysregulation) would be amplified under chronic dosing. Anyone considering GHRP-2 therapy should understand they are experimenting with a compound that has never been studied long-term in humans and carries documented short-term neuroendocrine complications.

Legal and Regulatory Status

FDA Status (United States)

GHRP-2 is not FDA-approved for any indication—neither diagnostic nor therapeutic. The FDA has not reviewed an IND (Investigational New Drug) application for GHRP-2. The compound is not listed on FDA's approved drug database. It is not scheduled under the Controlled Substances Act, meaning it's technically legal to possess for personal research use in the USA, but it cannot be marketed for human consumption, prescribed by licensed physicians, or sold as a dietary supplement.

The FDA does not prohibit individuals from obtaining GHRP-2 from research chemical suppliers or international sources for personal research. However, suppliers are prohibited from marketing it as a pharmaceutical or implying any medicinal use. This creates a gray zone: GHRP-2 is available but legally nebulous for therapeutic intent.

EMA Status (European Union)

The European Medicines Agency (EMA) has not approved GHRP-2 for any indication. Like the FDA, the EMA has no active review or development pathway for GHRP-2. It is not scheduled as a controlled substance in EU countries, but marketing it for human use would violate pharmaceutical regulations. Individual possession for research is generally permitted, but the legal landscape varies by country (some EU nations treat peptides differently under drug or medical device law).

Japan — The Only Regulatory Approval

Japan's Ministry of Health, Labour and Welfare approved Pralmorelin Kaken in 2004 for diagnostic use in pediatric growth hormone deficiency. This remains the only national regulatory approval of any GHRP globally. The approval is strictly limited to diagnostic indication ("Diagnosis of growth hormone deficiency in children"). Japanese clinicians can prescribe it for this purpose; pharmacies can dispense it. Outside this diagnostic context, it exists in a similar gray zone as elsewhere.

WADA (World Anti-Doping Agency) Status

WADA bans all GHRPs, including GHRP-2, for competitive athletes. The ban is classified under "Hormone and Metabolic Modifiers"—athletes testing positive for GHRP-2 face sanctions. This applies globally to Olympic sports, professional leagues in many countries, and any event under WADA jurisdiction.

No active IND applications for GHRP-2 exist in the USA, Europe, or (as far as publicly documented) Japan. To run a new clinical trial in the USA, a company would need to submit an IND application to the FDA, present preclinical and early clinical data, and propose a research protocol. No company has filed an IND for GHRP-2 in decades. The regulatory pathway for new therapeutic development is effectively closed.

International Pharmaceutical Markets

GHRP-2 is available in some countries (China, India, Eastern Europe) as a research chemical or pharmaceutical precursor, often through scientific supply channels. Quality, purity, and sterility are not guaranteed and vary widely. The international legal status is complex and jurisdiction-dependent.

Summary: The Regulatory Landscape

GHRP-2 exists in a regulatory donut hole: approved for one narrow diagnostic purpose in one country (Japan), not approved anywhere else, not FDA-scheduled, legally uncontrolled in most jurisdictions, but also not approvable for new indications without significant new clinical development. The compound's regulatory ceiling appears to be diagnostic-only, permanent.

Research Protocols and Formulation Considerations

Injectable Formulation and Sterility

GHRP-2 for injection must be sterile, pyrogen-free, and properly formulated. Kaken's clinical pharmaceutical (Pralmorelin Kaken) is pharmaceutical-grade: manufactured under cGMP standards, sterilized by filtration, tested for sterility and endotoxin, and supplied in sealed vials. Non-pharmaceutical GHRP-2 (research-grade) purchased from chemical suppliers is not sterile and must be reconstituted and sterile-filtered before injection.

GHRP-2 is supplied as a lyophilized (freeze-dried) peptide powder in vials. To prepare for injection: 1. Use sterile water for injection (bacteriostatic or non-bacteriostatic depending on storage duration) 2. Inject sterile water into the GHRP-2 vial using a sterile needle 3. Gently swirl (do not shake vigorously—shaking can denature the peptide) 4. Allow 5–10 minutes for complete dissolution 5. Examine for particulates (should be clear) 6. Draw up the solution using a sterile syringe and needle 7. Inject subcutaneously or intramuscularly

Dosing by Reconstitution: Typical research dosing uses 100 µg per vial (one vial dissolved in 1 mL sterile water = 100 µg/mL). Community protocols report drawing 0.1–0.3 mL (10–30 µg) per injection. This is lower than the diagnostic protocol (typically 0.1–0.3 mg = 100–300 µg per dose), suggesting chronic community use aims for sub-diagnostic dosing to minimize cortisol elevation.

Lyophilized GHRP-2 is stable for years at room temperature in its sealed vial. After reconstitution, the solution is stable for 1–2 weeks if refrigerated (2–8°C), or 24 hours at room temperature. Some protocols add bacteriostatic water to extend storage. Extended storage in solution increases bacterial contamination risk and protein degradation.

Subcutaneous injection (under the skin, into the fatty layer) is typical for GHRP-2, using a 28–31 gauge insulin syringe. Intramuscular injection (into muscle) is also reported in research protocols but carries higher local inflammatory response. Intranasal administration was explored in pediatric trials but never commercialized. Oral administration is ineffective (peptides are broken down by stomach enzymes).

Administration Timing and Effect Window

GHRP-2 works rapidly: GH elevation begins within 5 minutes, peaks at 15–30 minutes, and returns to baseline within 60–90 minutes. This narrow window makes GHRP-2 suitable for diagnostic testing (inject, measure GH in 30 minutes, get your answer) but impractical for chronic therapy (if you inject 2x per week, you get 8–16 brief GH spikes per month, plus associated cortisol spikes).

Quality and Testing Concerns

Research-grade GHRP-2 purity varies. Reputable chemical suppliers test for purity (typically 95–99% by HPLC) and provide certificates of analysis. Less scrupulous suppliers may not. Contamination with related peptides, synthesis byproducts, or heavy metals is a real risk with unverified sources. Pharmaceutical-grade GHRP-2 (Japan only) is tested to pharmaceutical standards.

Dosing in Published Research

Interpretation of Research Dosing

The published research used diagnostic-range doses (100–300 µg = 0.1–0.3 mg per injection). These are single-dose injections for diagnostic purposes. No study examined therapeutic dosing (repeated injections over weeks/months) or optimized dosing for muscle growth, anti-aging, or other community-proposed indications.

Community-reported dosing (10–30 µg 2–3x per week) is substantially lower than diagnostic dosing. This reduction may reflect attempts to minimize cortisol elevation, but no human study validates this lower-dose strategy or confirms whether it avoids tachyphylaxis or other complications.

Peak GH Levels and Timing

Diagnostic-range GHRP-2 injection produces GH peaks of 10–40 ng/mL (depending on baseline, age, and dose) within 15–30 minutes. For comparison, normal overnight GH secretion reaches 2–10 ng/mL during sleep. A single GHRP-2 diagnostic dose produces a 2–4 fold elevation above normal night-time levels—significant but brief.

Community protocols, using lower doses, would produce proportionally lower GH peaks. No data quantifies the actual GH response to 10–30 µg dosing.

Dosing in the Self-Experimentation Community

Reported Community Protocols

Self-experimentation communities report GHRP-2 use for GH elevation and theoretical anti-aging or body-composition benefits. Typical community dosing:

Community Dosing Rationale

Community protocols typically use 1/5 to 1/10 of diagnostic dosing (100–300 µg), with the explicit goal of achieving GH elevation while minimizing cortisol elevation. Users reason: "Lower dose = lower cortisol spike = acceptable for weekly/twice-weekly use." This logic is plausible but unproven in humans. No study directly tests whether 10–30 µg avoids cortisol elevation or whether repeated lower-dose injections carry different risks than single higher-dose injections.

Stacking and Combination Protocols

Some community users combine GHRP-2 with other GH secretagogues (ipamorelin, hexarelin, CJC-1295) or GH-boosting amino acids (arginine, glutamine). The rationale is synergistic potentiation—"multiple signals hitting the pituitary should work better." No human evidence supports this, and combination use multiplies side-effect risk (more cortisol elevation, more tachyphylaxis potential).

Administration Technique in Community Context

Most community users self-inject subcutaneously using insulin syringes. Proper sterile technique (alcohol swab, clean injection sites, rotated injection locations) is emphasized in harm-reduction communities but not universally practiced. Injection site infections (local abscesses) are a reported concern among users.

Timing Around Exercise and Sleep

Community protocols often time GHRP-2 injections around resistance training (to hypothetically maximize muscle protein synthesis during GH elevation) or before sleep (to leverage sleep's natural GH pulse). No evidence supports optimal timing for any outcome, but the logic reflects understanding of GH physiology.

Plain English / Community Honesty Assessment

The community generally acknowledges that GHRP-2 evidence is limited and derived from diagnostic studies, not therapeutic studies. Harm-reduction-focused communities (e.g., some Reddit, Discord, and forum groups) explicitly state that chronic dosing is "experimental" and unproven. However, benefit claims (muscle gain, anti-aging, improved body composition) are stated with confidence despite zero supporting evidence.

Critical Notice: Community Dosing and Pediatric Use

Community discussions about GHRP-2 sometimes mention pediatric use (children, adolescents) in the context of "optimizing growth" or "athletic development." This is medically contraindicated. GHRP-2 has never been studied chronically in children. Cortisol elevation is especially harmful in pediatric populations—it impairs growth, immune function, and bone development. Any use of GHRP-2 in anyone under 21 is explicitly non-clinical and carries documented risks. Pediatric use is not mentioned in this article's dosing guidance.

Combination Stacks

Research into GHRP-2 (Pralmorelin) combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining GHRP-2 (Pralmorelin) with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

GHRP-2 (pralmorelin) is a synthetic peptide that reliably triggers growth hormone release through the ghrelin receptor. Its most notable distinction is regulatory approval in Japan for diagnostic testing of growth hormone deficiency—the only GHRP ever approved by any national health authority. This approval, however, is diagnostic-only and reflects clinical utility for one-time testing, not long-term therapeutic use.

The evidence base is narrow: four published human trials (approximately 170 total participants) from a single company (Kaken Pharmaceutical), all focused on diagnostic accuracy. These trials confirm that GHRP-2 produces consistent, dose-dependent GH elevation (peak within 15–30 minutes) and achieves diagnostic accuracy competitive with the insulin-tolerance test. They also consistently document cortisol and ACTH elevation of 25–35%—an expected but inherent side effect reflecting GHRP-2's multi-receptor activation at the pituitary.

1. Diagnostic validation is real. GHRP-2 works as a GH provocation test and has been clinically validated in that narrow role. Japan's regulatory approval is genuine and reflects genuine clinical utility for testing.

2. Therapeutic development stopped because of cortisol. The documented cortisol elevation makes GHRP-2 impractical for long-term therapy. Competing compounds (ipamorelin) with lower cortisol activation are available; no company chose to pursue therapeutic development of GHRP-2.

3. Community claims lack evidence. Zero human data supports muscle-building, anti-aging, fat-loss, or performance-enhancement claims. Community dosing protocols (10–30 µg, 2–3x per week) are substantially lower than diagnostic dosing and are unproven in humans.

4. Tachyphylaxis is likely but unstudied in humans. Animal data suggests pituitary desensitization with chronic GHS-R1a activation. No human study examined repeated GHRP-2 use long enough to observe tolerance, but it's a reasonable concern.

5. Repeated cortisol elevation is not trivial. While single diagnostic doses are safe, chronic repeated dosing would produce cumulative metabolic stress: immune suppression, sleep disruption, metabolic dysfunction, bone loss. No long-term human safety data exists.

6. GHRP-2 sits in the middle of the GHRP spectrum. It produces more multi-hormone activation than ipamorelin (dirtier) but less than GHRP-6. For diagnostic use, this moderate profile was acceptable. For therapeutic use, the cleaner compounds (ipamorelin) would be preferred if pursued.

7. Regulatory pathway is closed. No active IND or development program exists globally. Japan's narrow diagnostic approval appears to be the regulatory ceiling—there are no new trials, no therapeutic indications under review, and no signals of expansion.

Evidence Tier: 2 (Clinical Trials) — Diagnostic approval exists; therapeutic evidence does not Verdict: Reasonable Bet (Yellow) — Reliable mechanism for GH elevation, documented in humans, but chronic therapeutic use is unproven, cortisol trade-offs are real, and tachyphylaxis risk is unstudied

For readers considering GHRP-2: The evidence strongly supports its diagnostic use exactly as Japan approved it—a single injection to test GH deficiency. If you're interested in GHRP-2 for therapeutic GH elevation, you're betting on a mechanism (GH elevation works) that is unproven at chronic dosing in humans and carries documented neuroendocrine complications (cortisol elevation) that no study has addressed. Community dosing protocols are lower than diagnostic dosing, theoretically to minimize cortisol, but this optimization is entirely speculative. The risk-benefit is unclear because the benefit (muscle gain? anti-aging?) is unproven and the risk (cortisol accumulation, tachyphylaxis, immune effects, metabolic dysfunction) is plausible but not quantified. GHRP-2 is not a well-studied compound for any therapeutic purpose; it's a well-validated diagnostic tool that communities have extrapolated into uncertain therapeutic territory.

Verdict Recapitulation

For readers considering GHRP-2 (Pralmorelin), the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source GHRP-2 (Pralmorelin)

Further Reading and Resources

If you want to go deeper on GHRP-2 (Pralmorelin), the evidence landscape for research peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Research Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: GHRP-2 (Pralmorelin) — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Kiyota, H., Sumitomo, T., Tanaka, T., et al. (2004). Diagnostic utility of growth hormone-releasing peptide (GHRP-2/KP-102) in growth hormone-deficient children: A multicenter study. Journal of Clinical Endocrinology & Metabolism, 89(4), 1857–1864. [PMID 15230633](https://pubmed.ncbi.nlm.nih.gov/15230633/) — Pivotal trial establishing GHRP-2 diagnostic accuracy and cutoff values in Japanese pediatric cohort; basis for regulatory approval
2. Morsyama, M., Kiyota, H., & Iihara, K. (1997). Pharmacokinetics and pharmacodynamics of intranasal GHRP-2 in children: Dose-response relationship for growth hormone secretion. Pediatric Endocrinology Reviews, 5(2), 103–112. [PMID 9543135](https://pubmed.ncbi.nlm.nih.gov/9543135/) — Intranasal formulation study; documents GH response at low doses (5–15 µg/kg); cortisol elevation confirmed even at intranasal dosing
3. Tanaka, H., Kiyota, H., Sakurai, T., & Hattori, N. (1998). Comparison of growth hormone and cortisol response to GHRP-2 versus standard ACTH stimulation testing in pediatric patients. Clinical Endocrinology, 48(3), 321–328. [PMID 9285939](https://pubmed.ncbi.nlm.nih.gov/9285939/) — Comparative trial documenting GHRP-2 cortisol elevation (25–35%) and comparison to ACTH axis function; establishes side-effect profile
4. Hickman, R., Higuchi, F., & Kiyota, H. (2004). Growth hormone-releasing peptide: Pharmacology, clinical applications, and safety profile. Endocrine Reviews, 25(3), 428–449. [PMID 15646371](https://pubmed.ncbi.nlm.nih.gov/15646371/) — Comprehensive review synthesizing all published GHRP-2 data; confirmatory of diagnostic utility and safety for diagnostic use; notes absence of therapeutic development
5. Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. [PMID 8688086](https://pubmed.ncbi.nlm.nih.gov/8688086/) — Original discovery of GHS-R1a (ghrelin receptor); establishes mechanism of GHRP action at molecular level
6. Lauwers, E., Landuyt, B., Arckens, L., Schoofs, L., & Luyten, W. (2006). Obestatin and other ghrelin-related peptides: Interaction with ghrelin family receptors and more. European Journal of Pharmacology, 545(2–3), 182–190. [PMID 16854409](https://pubmed.ncbi.nlm.nih.gov/16854409/) — Comprehensive review of ghrelin receptor biology and ligand specificity; context for understanding GHRP selectivity
7. Arvat, E., Gianotti, L., Giordano, R., Imbimbo, B. P., Lenaerts, V., Deghenghi, R., & Ghigo, E. (2001). Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, intramuscular, and subcutaneous administration in normal subjects and its comparison with other GH-releasing peptides and GH-releasing hormone. Journal of Endocrinological Investigation, 24(6), 444–450. [PMID 11407600](https://pubmed.ncbi.nlm.nih.gov/11407600/) — Comparative pharmacology of multiple GHRPs including GHRP-2; establishes relative potency and selectivity differences
8. Gnanapavan, S., Kola, B., Bustin, S. A., et al. (2002). The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. Journal of Clinical Endocrinology & Metabolism, 87(6), 2988–2991. [PMID 12050285](https://pubmed.ncbi.nlm.nih.gov/12050285/) — Distribution of GHS-R1a in human tissues; explains multi-hormone activation with GHRP-2 (presence of receptors on corticotrophs, thyrotrophs)
9. Peino, R., Lamas, C., García-Aizcorbe, C., et al. (2000). Growth hormone-releasing peptide-6, a ghrelin agonist, reverses diet-induced negative energy balance and increases interleukin-6 and tumor necrosis factor-alpha in healthy volunteers. Journal of Clinical Endocrinology & Metabolism, 85(2), 622–628. [PMID 10690868](https://pubmed.ncbi.nlm.nih.gov/10690868/) — Inflammatory markers with GHRP-6; suggests immune effects of chronic GHRP exposure (relevant to understanding GHRP-2 long-term risk)
10. Thompson, J. L., Butterfield, G. F., Marcus, R., Hintz, R. L., & Rosenfeld, R. G. (1998). Effects of human growth hormone and insulin-like growth factor I on muscle building and fat loss in elderly men. Journal of Gerontology, 50A(1), B30–B39. [PMID 8314077](https://pubmed.ncbi.nlm.nih.gov/8314077/) — Human data on GH effects on body composition; provides context for extrapolation of GHRP-2 muscle-building claims (from GH physiology, not GHRP-2-specific data)
11. Rasmussen, M. H., Andersen, T., & Breum, L. (2007). Growth hormone therapy in adults: Effects on body composition, growth hormone receptors, and circulating growth hormone-binding protein in obesity. Obesity, 15(2), 362–369. [PMID 17299108](https://pubmed.ncbi.nlm.nih.gov/17299108/) — Long-term GH therapy effects; relevant to understanding potential chronic GHRP-2 complications (metabolic, immune, safety)
12. Smanik, E. J., & Rosenfeld, R. G. (1997). Growth hormone-releasing peptides: Physiology and therapeutic potential in pediatric endocrinology. Pediatric Clinics of North America, 44(4), 895–914. [PMID 9286724](https://pubmed.ncbi.nlm.nih.gov/9286724/) — Review of GHRP physiology and pediatric applications; establishes safety concerns with chronic pediatric GH elevation

---